Protective role of nutraceuticals against myocarditis
Enayati A, Banach M, Jamialahmadi T, Sahebkar A; endorsed by the International Lipid Expert Panel (ILEP).
Enayati A, Banach M, Jamialahmadi T, Sahebkar A; endorsed by the International Lipid Expert Panel (ILEP).
Inflammation plays a central role in the pathogenesis and clinical manifestations of atherosclerosis. Randomized controlled trials have investigated the potential benefit of colchicine in reducing cardiovascular (CV) events in patients with coronary artery disease (CAD) but produced conflicting results. The aim of this meta-analysis was to evaluate the efficacy and safety of colchicine in patients […]
Familial hypercholesterolaemia (FH) is a genetic and complex multifactorial lipid disorder, which increases the risk of premature atherosclerosis and coronary artery disease. FH is still underdiagnosed and undertreated globally and clinical strategies for the treatment and management of pediatric patients with this disorder are still far from being optimal. The objective of this position paper […]
Fig. 1. Direct potential causes of myocarditis. Myocarditis is an inflammatory disease of the myocardium that mostly affects young adults. The disease is commonly caused by viral infection, medications, autoimmune disorders, and inflammatory conditions. Nearly 50% of the cases of myocarditis are due to post-viral immune response in a setting of an identifiable or non-identifiable […]
Bjelakovic B, Stefanutti C, Reiner Ž, Watts GF, Moriarty P, Marais D, Widhalm K, Cohen H, Harada-Shiba M, Banach M.
Banach M.
A new paper has been published about the association of statin use in older people primary prevention group with risk of cardiovascular events and mortality. The meta-analysis provides a detailed review of existing evidence and observational studies conducted to systematize knowledge on this topic. Please feel invited to learn more about the paper here.
Role of omega-6 and omega-3 fatty acids on inflammatory pathways Based on the available evidence, we are able to delineate specific nutraceuticals that may be important in reducing markers of inflammatory response. ILEP Experts discussed the impact of nutraceuticals on the induction of inflammation. The paper can be accessed here.
ILEP Experts would like to present a meta-analysis conducted to test and determine the potential benefit in reducing cardiovascular events from administration of colchicine in patients with coronary artery disease. The results of the study bring valuable knowledge related to this alkaloid and its use. You can read the publication here.
Cybulska B, Kłosiewicz-Latoszek L, Penson PE, Nabavi SM, Lavie CJ, Banach M; International Lipid Expert Panel (ILEP)